688739 Stock Overview
A biotechnology company, engages in the research and development, production, and sales of vaccines for human use in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Liaoning Chengda Biotechnology Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.24 |
| 52 Week High | CN¥34.27 |
| 52 Week Low | CN¥21.95 |
| Beta | 0.71 |
| 11 Month Change | 5.26% |
| 3 Month Change | 12.42% |
| 1 Year Change | -19.00% |
| 33 Year Change | -65.26% |
| 5 Year Change | n/a |
| Change since IPO | -65.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688739 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.2% | -4.3% | -3.9% |
| 1Y | -19.0% | -17.7% | 4.0% |
Return vs Industry: 688739 underperformed the CN Biotechs industry which returned -14.2% over the past year.
Return vs Market: 688739 underperformed the CN Market which returned 6.7% over the past year.
Price Volatility
| 688739 volatility | |
|---|---|
| 688739 Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.4% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 688739 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688739's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,775 | Yu Mao | www.cdbio.cn |
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use in China. It offers Chengda Suda human rabies and Chengda Libao Human Type B inactivated encephalitis vaccines.
Liaoning Chengda Biotechnology Co.,Ltd. Fundamentals Summary
| 688739 fundamental statistics | |
|---|---|
| Market cap | CN¥11.21b |
| Earnings (TTM) | CN¥332.10m |
| Revenue (TTM) | CN¥1.72b |
33.8x
P/E Ratio6.5x
P/S RatioIs 688739 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688739 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.72b |
| Cost of Revenue | CN¥371.88m |
| Gross Profit | CN¥1.35b |
| Other Expenses | CN¥1.01b |
| Earnings | CN¥332.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.81 |
| Gross Margin | 78.35% |
| Net Profit Margin | 19.33% |
| Debt/Equity Ratio | 0% |
How did 688739 perform over the long term?
See historical performance and comparison